Zeta BAP1 Antibody. Zeta’s rabbit recombinant antibody binds to BAP1, a tumor suppressor that is involved in transcriptional regulation, chromatin modulation, and possibly via the ubiquitin-proteasome system and the DNA damage response pathway. BAP1 expression can differentiate malignant mesothelioma (nuclear negative) versus reactive mesothelial proliferation.
BAP1 (BRCA1-Associated Protein 1) was initially identified as a protein that binds to BRCA1. BAP1 is a tumor suppressor that is believed to mediate its effects through chromatin modulation, transcriptional regulation, and possibly via the ubiquitin-proteasome system and the DNA damage response pathway. Germline mutations of BAP1 confer increased susceptibility for the development of several tumors, including uveal melanoma, epithelioid atypical Spitz tumors, cutaneous melanoma, and mesothelioma. Somatic BAP1 mutations are seen in cutaneous melanocytic tumors (epithelioid atypical Spitz tumors and melanoma, uveal melanoma, mesothelioma, clear cell renal cell carcinoma, and other tumors. BAP1 immunohistochemistry is particularly useful in differentiating malignant mesothelioma (nuclear negative) versus reactive mesothelial proliferatio (nuclear positive).
Zeta Corporation is a leader in recombinant monoclonal IVD antibodies for immunohistochemistry (IHC) offering 400+ tumor and tissue specific relevant products developed by a pathologist for pathologists. Visit Precision Recombinant Antibodies – IVD Antibodies – About Zeta Corporation (zeta-corp.com) to learn more about Zeta Corporation.